Browsing by Author "Salman, Patricio"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Del macro al microcarcinoma tiroideo : cambios en las características de presentación del cáncer de tiroides en un centro universitario chileno en 20 años
    (2013) Mosso Gómez, Lorena; Campusano Montaño, Claudia; González Díaz, Hernán; Domínguez Ruiz-Tagle, José Miguel; Salman, Patricio; Suazo, Valeria; Solar González, Antonieta Alejandra; Cerda, Jaime
  • Thumbnail Image
    Item
    Guidelines of the Chilean Endocrinology Society for the correct clinical use of bone densitometry
    (SOC MEDICA SANTIAGO, 2018) Barberan M, Marcela; Campusano M, Claudia; Trincado M, Patricio; Oviedo G, Sofia; Brantes G, Sergio; Sapunar Z, Jorge; Canessa, Jose; Cid, Pia; Escobar, Freddy; Eugenin, Daniela; Florenzano, Pablo; Gajardo, Hector; Gonzalez, Gilberto; Illanes, Francisca; Jimenez, Beatriz; Martinez, Carolina; Miranda, Edith; Rivera, Sandra; Salman, Patricio; Trejo, Pamela; Velasco, Soledad
    Osteoporosis is a silent and frequent disease, which increases fracture risk Approximately half of women and one of five men over 50 years old will suffer an osteoporotic fracture throughout their lives. Dual-energy x-ray absorptiometry (DXA) allows a real bone mineral density (BMD) measurement in different parts of the skeleton and is considered the "gold standard" for quantifying osteoporosis with high accuracy and precision. The Board of the Chilean Society of Endocrinology and Diabetes (SOCHED) required from the Bone Disease Study Group to develop a consensus about the "Correct use of bone densitometry in clinical practice in Chilean population". Therefore, we elaborated 25 questions which addressed key aspects about the indications for a DXA scan, and the details of how to perform and report this test. Since some of the evidence obtained was of low quality or inconclusive, we decided to create a multidisciplinary group of national experts in osteoporosis to develop a consensus in this subject. The group consisted of 22 physicians including endocrinologists, gynecologists, geriatricians, radiologists, rheumatologists and nuclear medicine specialists. Using the Delphi methodology to analyze previously agreed questions, we elaborated statements that were evaluated by the experts who expressed their degree of agreement. The final report of this consensus was approved by the SOCHED board.
  • No Thumbnail Available
    Item
    Plasma insulin-like growth factor-II (IGF-II) and IGF-II/IGF-I ratio in a chilean case of Doege-Potter Syndrome
    (2023) Tobar, Hugo E.; Ibaceta, Rodrigo; Figueroa, Ana-Maria; Quinones, Veronica; Iniguez, German; Salman, Patricio; Serrano, Valentina; Salinas, Lorena; Santos, Jose Luis
    Introduction: Doege-Potter syndrome is a rare clinical entity characterized by recurrent hypoglycemic events caused by non-pancreatic tumors secreting an incompletely processed high-molecular-weight form of Insulin-like Growth factor-II (IGF-II). Aim: To report IGF-II and IGF-I circulating levels in a Chilean case of Doege-Potter syndrome and control individuals, and to identify the high-molecular-weight form of IGF-II. Methods: We measured IGF-II and IGF-I plasma levels using enzyme-linked immunoassays (ELISA) in the patient and ten controls. We identified the high-molecular-weight form of IGF-II performed by Western blot. Results: The plasma concentration of IGF-II in the patient was 868.9 ng/mL, which is only slightly > 80th percentile of controls (681,4 +/- 212,8 ng/mL; mean +/- standard deviation). In contrast, IGF-I plasma concentration in the patient was 17.6 ng/mL, which is notoriously lower than the corresponding levels in controls (109.1 +/- 19.1 ng/mL). The IGF-II/IGF-I ratio in the patient was 49.4 (normal value < 10), which is 7.8 times higher compared to the average ratio of controls (6.3 +/- 1.5). The high-molecular form of IGF-II presence in samples was confirmed through Western blot. Conclusions: The plasma IGF-II/IGF-I ratio better indicates the Doege-Potter syndrome's metabolic impairment than isolated measurements of circulating IGF-II or IGF-I levels.